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1. Abbreviations 
ACN: acetonitrile, AFM: atomic force microscopy, All: allyl, CP: cyclic peptide, DCM: dichloromethane, DIEA: 
N,N-diisopropylethylamine, DMF: N,N-dimethylformamide, ESI: electrospray ionisation, Fmoc: 9-
fluorenylmethoxycarbonyl, HOBt: hydroxybenzotriazole, HR-MS: high resolution mass spectrometry, HPLC-
MS: high performance liquid chromatography-mass spectrometry, HBTU: N,N,N’,N’-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate, NMR: nuclear magnetic resonance spectroscopy, OAc: 
acetate, Ph: phenyl, PyAOP: (7-azabenzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate, 
SPPS: solid phase peptide synthesis STEM: scanning transmission electron microscopy, TFA: trifluoroacetic 
acid, ThT: thioflavin T, TIS: triisopropylsilane. 
2. Materials and methods 
Chemical reagents were acquired from Acros Organics, Aldrich, Fisher Scientific, Iris Biotech and Novabiochem. 
Dichloromethane was dried under reflux over calcium hydride. D2O was purchased from EMD Millipore. Glass 
slides for fluorescence microscopy were obtained from Ibidi (Cat# 80827). TEM grids (Cu carbon type-B, 300 
mesh) and PELCO® mica discs for AFM were acquired from Ted Pella. 1H NMR spectra were recorded on a 
Varian 300 MHz spectrometer. Chemical shifts are reported in ppm (δ) referenced to D2O’s residual signal (δ = 
4.79). HPLC-MS analyses were carried out on an Agilent 1260 Infinity II fitted with an Agilent SB-C18 column 
and connected to a 6120 Quadrupole MS detector. HR-MS was acquired on a Bruker MicroTOF. 
Epifluorescence micrographs were taken with a Nikon Eclipse Ti (60x immersion objective, Excitation=475/35 
nm; Emission=530/43 nm). STEM images were acquired on a FESEM Ultra plus (Zeiss) operating at 20 kV from 
unstained samples. AFM analysis was carried out on a NX-10 microscope in non-contact mode and using ACTA 
10M cantilevers (Park Systems). 
3. Cyclic peptide synthesis and purification 
Cyclic peptides were prepared manually in solid phase. Rink Amide resin was swollen in DMF for 30 min and 
then treated with piperidine 20% v/v in DMF (3 mL) to remove the Fmoc protecting group. The resin was washed 
with DMF (3 x 3 mL) and a solution of Fmoc-L-Glu(OH)-OAll (163.6 mg, 0.1 mmol), HBTU (132.5 mg, 0.35 
mmol) and DIEA (95 µL, 0.6 mmol) in DMF (3 mL) was added over the resin and shaken for 1 h. Then the 
mixture was filtered and washed with DMF (3 x 3mL) and DCM (3 x 3 mL). We followed cycles of Fmoc removal 
(2 mL of piperidine 20% v/v in DMF for 15 min) and amino acid coupling (0.4 mmol of amino acid, 0.35 mmol 
HBTU and 0.6 mmol DIEA in DMF for 30 min) with their respective washes (DMF 3 x 3 mL). 
For OAll removal, the resin was washed with DMF and DCM (3 x 3 mL) and then reacted with a solution of PPh3 
(39.3 mg, 0.15 mmol), N-methylmorpholine (110  μL, 0.01 mmol) and phenylsilane (123 μL, 1.0  mmol) and 
Pd(OAc)2 (6.7 mg, 0.03 mmol) in dry DCM (4 mL) overnight (16-20 h). The resin was then washed with DCM (3 
x 3 mL) and DIEA in DMF (2% v/v, 3 x 3 mL), and soaked in a solution of sodium diethyldithiocarbamate (0.5% 
w/v in DMF, 2 x 3 mL) for 30 min to remove all traces of Pd. Finally, the resin was stirred with piperidine/DMF 
(20% v/v, 3 mL) for 30 min for N-terminal Fmoc removal.  
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Cyclisation was carried out by reacting a solution of PyAOP (208.6 mg, 0.4 mmol) and DIEA (95.1 mL, 0.6 
mmol) in DMF (3 mL) for 2 h. After washing with DMF (3 x 3 mL) and DCM (3 x 3 mL), the cyclisation was 
repeated twice more in the same conditions. 
The peptide was cleaved from the resin by addition of a freshly prepared TFA cocktail (4 mL, TFA:DCM:H2O:TIS, 
0.9:0.05:0.025:0.025), this mixture was shaken for 2 h and then filtered. The resin was washed with TFA (0.5 
mL) twice and concentrated under nitrogen. The concentrated reaction crude was precipitated dropwise into 40 
mL of cold diethyl ether under stirring. The resulting suspension was centrifuged and the pellet was then 
dissolved in a 1:0.25 mixture of MilliQ H2O:ACN and purified by semipreparative HPLC using a Phenomenex 
Luna C18 100Å column [gradient of A (H2O+0.1% v/v TFA) : B (ACN+0.1% v/v TFA)→95:5 (0 min) to 25:75 (30 
min)]. Peptide fractions were concentrated in vacuo to remove ACN and TFA and the remaining solution was 
freeze dried.  
A white powder was obtained for all cyclic peptides: CPA (35 mg, 36 %); CPL (40 mg, 40 % ); CPF (41 mg, 39 
%); CP2F (44 mg, 38 %); CP3F (39 mg, 35 %); CPoE (41 mg, 38 %); CP2E2H (38 mg, 35 %); CPK (22 mg, 21 %); 
CP4E (24 mg, 22 %). 
 
Scheme S1. a) Rink Amide resin functionalisation: i. Piperidine 20% v/v in DMF, 30 min; ii.  Fmoc-L-Glu-OAll, 
HBTU, DIEA, DMF, 1 h. b) Peptide elongation: i. Piperidine 20% v/v in DMF, 15 min; ii. Fmoc-amino acid, HBTU, 
DIEA, DMF, 30 min. (Repeat 7 cycles). c) Cyclisation: i. OAllyl removal: Pd(OAc)2, PPh3, phenylsilane, 4-
methylmorpholine, DCM, overnight (16-20 h); ii. Fmoc removal: piperidine 20% v/v in DMF, 30 min; iii. Peptide 
cyclisation: PyAOP, DIEA, DMF, 2 h (repeat twice). d) Peptide cleavage: TFA, DCM, H2O, TIS, 2 h.   
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4. Cyclic peptide characterisation 
4.1. CPA 
UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% TFA; B = ACN + 0.1% TFA; Gradient (A:B): 100:0 (0 min) → 25:75 
(21 min); Rt = 9.5 min; m/z = 958.5 ([M+H]+), 479.8 ([M+2H]2+). 
Figure S1.  a) Structure of CPA; b) Chromatogram after purification; c) MS spectrum of the peak. 
HR-MS (ESI, +eV) m/z = 958.4741 (calculated for [M+H]+); 958.4744 (found). 
1H-NMR (300 MHz, D2O) δ: 0.78-0.95 (m, 17H, Leu i-Bu x2, Ala-CH3), 1.31-1.38 (m, 4H, Leu-CH2), 1.49-1.69 
(m, 4H, Glu-CH2- x2), 1.82-2.13 (m, 4H, Gln x2), 2.27-2.34 (m, 4H, Glu-CH2- x2), 3.01-3.43 (m, 4H, His-CH2- 
x2), 4.17-4.47 (m, 8H, Hα), 7.22-7.34 (m, 2H, His-CH= x2), 8.66 (s, 2H, His-CH= x2) ppm. 
 
Figure S2. 1H NMR (300 MHz) of CPA in D2O. 
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4.2. CPL 
UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% TFA; B = ACN + 0.1% TFA; Gradient (A:B): 100:0 (0 min) → 25:75 
(21 min); Rt =11.1 min; m/z = 1000.5 ([M+H]+), 500.8 ([M+2H]2+). 
Figure S3. a) Structure of CPL; b) Chromatogram after purification; c) MS spectrum of the peak. 
HR-MS (ESI, +eV): m/z = 1000.5211 (calculated for [M+H]+); 1000.5206 (found). 
1H-NMR (300 MHz, D2O) δ: 0.78-0.95 (m, 27H, Leu x3), 1.49-2.37 (m, 12H, Glu x2, Gln), 3.01-3.44 (m, 4H, His-
CH2- x2), 4.18-4.76 (m, 8H, Hα), 7.28-7.31 (m, 2H, His-CH= x2), 8.66 (s, 2H, His-CH= x2) ppm. 
 
Figure S4. 1H NMR (300 MHz) of CPL in D2O. 
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4.3. CPF 
UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% TFA; B = ACN + 0.1% TFA; Gradient (A:B): 100:0 (0 min) → 25:75 
(21 min); Rt = 11.4 min; m/z = 1034.5 ([M+H]+), 517.8 ([M+2H]2+). 
Figure S5. a) Structure of CPF; b) Chromatogram after purification; c) MS spectrum of the peak. 
HR-MS (ESI, +eV): m/z = 1034.5054 (calculated for [M+H]+); 1034.5048 (found).  
1H-NMR (300 MHz, D2O) δ: 0.67-0.90 (m, 16H, Leu i-Bu x2, Leu-CH2- x2), 1.22-1.38 (m, 2H, Leu-CH- x2), 1.69-
2.41 (m, 12H, Glu x2, Gln), 2.88-3.25 (m, 4H, His-CH2- x2), 3.25-3.42 (m, 2H, Phe-CH2-), 4.01-4.68 (m, 8H, Hα), 
7.19-7.35 (m, 7H, His-CH= x2, Phe-CH= x2), 8.63 (s, 2H, His-CH= x2) ppm. 
 
Figure S6. 1H NMR (300 MHz) of CPF in D2O. 
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4.4. CP2F 
UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% TFA; B = ACN + 0.1% TFA; Gradient (A:B): 100:0 (0 min) → 25:75 
(21 min); Rt = 11.9 min; m/z = 1141.5 ([M+H]+), 571.3 ([M+2H]2+). 
Figure S7. a) Structure of CP2F; b) Chromatogram after purification; c) MS spectrum of the peak. 
HR-MS (ESI, +eV): m/z = 1141.4850 (calculated for [M+H]+); 1141.4845 (found): 
1H-NMR (300 MHz, D2O) δ: 1.77-2.02 (m, 8H, Gln, Glu-CH2- x2), 2.13-2.22 (m, 4H, Glu-CH2- x2), 2.76-3.26 (m, 
10H, Phe-CH2- x2, Trp-CH2-, His-CH2- x2), 4.11-4.70 (m, 8H, Hα), 7.02-7.45 (m, 17H, Phe-CH= x15, His-CH= 
x2), 8.53-8.65 (m, 2H, His-CH= x2) ppm. 
 
Figure S8. 1H NMR (300 MHz) of CP2F in D2O. 
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4.5. CP3F 
UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% TFA; B = ACN + 0.1% TFA; Gradient (A:B): 100:0 (0 min) → 25:75 
(21 min); Rt = 12.2 min; m/z = 1102.5 ([M+H]+), 551.8 ([M+2H]2+). 
Figure S9. a) Structure of CP3F; b) Chromatogram after purification; c) MS spectrum of the peak. 
HR-MS (ESI, +eV): m/z = 1102.4741 (calculated for [M+H]+), 1102.4737 (found). 
1H NMR (300 MHz, D2O) δ: 1.36-2.15 (m, 12 H, Glu, Gln), 2.62-3.25 (m, 10 H, His-CH2- x2, Phe-CH2- x2, Trp-
CH2-), 4.19-4.80 (m, 8H, Hα), 6.98-7.41 (m, 17H, Phe x3, His x2), 8.62 (s, 2H, His x2) ppm. 
 
Figure S10. 1H NMR (300 MHz) of CP3F in D2O. 
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4.6. CPoE 
UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% TFA; B = ACN + 0.1% TFA; Gradient (A:B): 100:0 (0 min) → 25:75 
(21 min); Rt = 10.9 min; m/z = 1073.5 ([M+H]+), 537.3 ([M+2H]2+). 
Figure S11. a) Structure of CPoE; b) Chromatogram after purification; c) MS spectrum of the peak. 
HR-MS (ESI, +eV): m/z = 1073.5163 (calculated for [M+H]+); 1073.5172 (found). 
1H-NMR (300 MHz, D2O) δ: 0.59-0.84 (m, 14H, Leu i-Bu x2, Leu-CH- x2), 1.15-1.35 (m, 4H, Leu-CH2- x2), 1.85-
2.38 (m, 12H, Glu x2, Gln), 2.97-3.43 (m, 6H, His-CH2- x2, Trp-CH2-), 3.80-4.70 (m, 8H, Hα), 7.11-7.18 (m, 2H, 
His-CH= x2), 7.18-7.37 (m, 3H, Trp-CH= x2, Trp-CH=), 7.40-7.69 (m, 2H, Trp-CH= x2), 8.67 (s, 2H, His-CH= 
x2) ppm.   
 
Figure S12. 1H NMR (300 MHz) of CPoE in D2O. 
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4.7. CP2E2H 
UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% TFA; B = ACN + 0.1% TFA; Gradient (A:B): 100:0 (0 min) → 25:75 
(21 min); Rt = 11.0 min; m/z = 1073.5 ([M+H]+), 537.4 ([M+2H]2+). 
Figure S13. a) Structure of CP2E2H; b) Chromatogram after purification; c) MS spectrum of the peak. 
HR-MS (ESI, +eV): m/z = 1073.5163 (calculated for [M+H]+); 1073.5155 (found). 
1H-NMR (300 MHz, D2O) δ: 0.49-0.82 (m, 14H, Leu i-Bu x2, Leu-CH- x2), 1.18-1.37 (m, 4H, Leu-CH2- x2), 1.86-
2.38 (m, 12H, Glu x2, Gln), 2.87-3.38 (m, 6H, His-CH2- x2, Trp-CH2-), 3.83-4.69 (m, 8H, Hα), 6.95-7.37 (m, 2H, 
His-CH= x2, 3H, Trp-CH= x3), 7.48 (d, J = 7.5 Hz, 1H, Trp-CH=), 7.61 (d, J = 7.5 Hz, 1H, Trp-CH=), 8.62 (s, 
2H, His-CH= x2) ppm.  
 
Figure S14. 1H NMR (300 MHz) of CP2E2H in D2O. 
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4.8. CPK 
UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% TFA; B = ACN + 0.1% TFA; Gradient (A:B): 100:0 (0 min) → 25:75 
(21 min); Rt = 11.2 min; m/z = 1055.6 ([M+H]+), 528.4 ([M+2H]2+). 
Figure S15. a) Structure of CPK; b) Chromatogram after purification; c) MS spectrum of the peak. 
HR-MS (ESI, +eV): m/z = 1055.5884 (calculated for [M+H]+); 1055.5877 (found). 
1H-NMR (300 MHz, D2O) δ: 0.41-0.91 (m, 12H, Leu i-Bu x2), 1.15-1.28 (m, 2H, Leu-CH- x2), 1.32-1.46 (m, 4H, 
Leu-CH2- x2), 1.47-2.38 (m, 24H, Glu x2, Lys-CH2- x6, Gln), 2.88-3.02 (m, 4H, Lys-CH2- x2), 3.19-3.35 (m, 2H, 
Trp-CH2-), 4.10-4.66 (m, 8H, Hα), 7.04-7.29 (m, 3H, Trp-CH= x3), 7.47-7.70 (m, 2H, Trp-CH= x2) ppm. 
 
Figure S16. 1H NMR (300 MHz) of CPK in D2O. 
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4.9. CP4E 
UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% TFA; B = ACN + 0.1% TFA; 100:0 (0 min) → 25:75 (21 min); Rt = 
12.2  min; m/z = 1057.5 ([M+H]+), 529.4 ([M+2H]2+). 
Figure S17. a) Structure of CP4E; b) Chromatogram after purification; c) MS spectrum of the peak. 
HR-MS (ESI, +eV): m/z = 1057.4837 (calculated for [M+H]+); 1057.4836 (found). 
1H-NMR (300 MHz, D2O) δ: 0.65-0.81 (m, 12H, Leu i-Bu x2), 1.20-1.29 (m, 2H, Leu-CH- x2), 1.34-1.46 (m, 4H, 
Leu-CH2- x2), 1.87-2.43 (m, 20H, Glu x4, Gln), 3.12-3.36 (m, 2H, Trp-CH2-), 4.01-4.43 (m, 8H, Hα), 7.03-7.34 
(m, 3H, Trp-CH= x3), 7.47-7.69 (m, 2H, Trp-CH= x2) ppm. 
 
Figure S18. 1H NMR (300 MHz) of CP4E in D2O. 
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Figure S19. Epifluorescence micrographs of CP2E2H in 20 mM sodium phosphate buffer adjusted at pH 7.4, 4.0 





Figure S20. Epifluorescence micrographs of CP4E in 20 mM sodium phosphate buffer adjusted at pH 7.4, 4.0 
or 2.0 (see insets) in presence of thioflavin-T (10 µM). Scale bars = 50 µm. 
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Figure S21. Epifluorescence micrographs of CP2E2H in 20 mM sodium phosphate buffer at pH 7.4 with 





Figure S22. Epifluorescence micrographs of CP4E in 20 mM sodium phosphate buffer at pH 7.4 with increasing 
concentrations of NaCl (see insets) in presence of thioflavin-T (10 µM). Scale bars = 50 µm. 
 
